Table 2

Incidence of end point events

Variable	P-years (1000)	Events	Incidence (1/1000)	95% CI		RR	95% CI
Current statin usage
No	67.78	118	1.74	1.44	2.09
Yes	11.17	18	1.61	0.95	2.55	0.93	0.56	1.52
Sex
Male	36.02	53	1.47	1.1	1.93
Female	42.93	83	1.93	1.54	2.4	1.31	0.93	1.85
Age
(0, 40]	19.92	10	0.50	0.24	0.92
(40, 50]	20.22	15	0.74	0.41	1.22	1.48	0.66	3.29
(50, 60]	17.11	24	1.40	0.90	2.09	2.79	1.34	5.84
(60, 70]	11.05	28	2.53	1.68	3.66	5.05	2.45	10.39
(70, Inf]	10.65	59	5.54	4.22	7.15	11.04	5.65	21.58
Insulin usage at baseline
No	77.83	133	1.71	1.43	2.03
Yes	1.12	3	2.68	0.55	7.83	1.57	0.50	4.92
Blood glucose lowering drug
No	76.71	124	1.62	1.34	1.93
Yes	2.24	12	5.37	2.77	9.37	3.32	1.84	6.00
Antithrombotic agent usage
No	76.7	120	1.56	1.30	1.87
Yes	2.25	16	7.11	4.06	11.55	4.55	2.70	7.66
Antiplatelet agents usage
No	77.87	126	1.62	1.35	1.93
Yes	1.08	10	9.27	4.44	17.05	5.73	3.01	10.91
Vitamin K antagonists usage
No	77.7	128	1.65	1.37	1.96
Yes	1.25	8	6.42	2.77	12.66	3.90	1.91	7.97
Blood glucose (mmol/L)
[2.4, 5.1]	24.79	36	1.45	1.02	2.01
(5.1, 5.6]	23.93	31	1.30	0.88	1.84	0.89	0.55	1.44
(5.6, 26.7]	18.69	48	2.57	1.89	3.40	1.77	1.15	2.72
Total cholesterol (mmol/L)
[1.9, 5.4]	23.71	36	1.52	1.06	2.10
(5.4, 6.3]	21.33	33	1.55	1.06	1.02	0.64	1.63	1.02
(6.3, 11.7]	22.38	46	2.06	1.50	1.35	0.88	2.09	1.35
HDL cholesterol (mmol/L)
[0.23, 1.13]	22.39	45	2.01	1.46
(1.13, 1.45]	22.45	33	1.47	1.01	0.73	0.47	1.15	0.73
(1.45, 3.41]	22.57	37	1.64	1.15	0.82	0.53	1.26	0.82
LDL cholesterol (mmol/L)
[0, 3.3]	22.56	34	1.51	1.04
(3.3, 4.2]	22.79	38	1.67	1.18	1.11	0.70	1.76	1.11
(4.2, 8.8]	22.06	43	1.95	1.41	1.29	0.82	2.03	1.29
Triglycerides (mmol/L)
[0.4, 1.1]	26.16	30	1.15	0.77
(1.1, 1.7]	21.84	45	2.06	1.50	1.80	1.13	2.85	1.80
(1.7, 16.6]	19.42	40	2.06	1.47	1.80	1.12	2.88	1.80
Ratio HDL/cholesterol
[3, 19]	23.92	48	2.01	1.48
(19, 25.7]	20.58	34	1.65	1.14	0.82	0.53	1.28	0.82
(25.7, 56]	22.91	33	1.44	0.99	0.72	0.46	1.12	0.72
C reactive protein (mg/L)
[0, 0.39]	22.26	22	0.99	0.62
(0.39, 1.41]	21.62	42	1.94	1.40	1.97	1.17	3.29	1.97
(1.41, 191]	20.53	40	1.95	1.39	1.97	1.17	3.32	1.97
Vitamin D₃ (nmol/L)
[5, 36]	20.55	35	1.70	1.19	2.37
(36, 50]	21.42	31	1.45	0.98	2.06	0.85	0.52	1.38
(50, 134]	21.15	37	1.75	1.23	2.41	1.03	0.65	1.63
Homocysteine (µmol/L)
[3.7, 9.7]	22.15	18	0.81	0.48	1.29
(9.7, 12.5]	21.82	32	1.47	1.00	2.07	1.80	1.01	3.22
(12.5, 111]	19.16	53	2.77	2.07	3.62	3.40	1.99	5.81
Insulin (mU/L)
[1, 5]	22.72	26	1.14	0.75	1.68
(5, 9]	22.67	45	1.99	1.45	2.66	1.73	1.07	2.81
(92 200]	19.64	33	1.68	1.16	2.36	1.47	0.88	2.00

RR with 95% CI based on univariate Poisson regression model.
Laboratory measurements in tertiles ‘[a,b)’ means that interval a–b is closed left and open right. The data on variables are collected at baseline.
HDL, high-density lipoprotein; LDL, low-density lipoprotein; RR, rate ratio.